| Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban. | |
| | |
MedLine Citation:
|
PMID: 14634048 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Platelet activation and subsequent aggregation play a key role in the pathogenesis of ischemic brain damage. Recent studies revealed that enhanced platelet activation is also observed after ischemia, suggesting that secondary thrombus formation might participate in the development of cerebral infarction. The binding of platelet glycoprotein GPIIb/IIIa (integrin alpha(IIb)beta3) to fibrinogen is the final common pathway in platelet aggregation. Therefore, GPIIb/IIIa antagonists might be useful in acute ischemic stroke as well as in the secondary prevention of ischemic stroke. In the present study, we evaluated the effect of three compounds, FK419 ((S)-2-acetylamino-3-[(R)-[1-[3-(piperidin-4-yl) propionyl] piperidin-3-ylcarbonyl] amino] propionic acid trihydrate), a novel nonpeptide GPIIb/IIIa antagonist, ozagrel, a selective thromboxane A(2) synthase inhibitor, and argatroban, a thrombin inhibitor, on middle cerebral artery (MCA) patency and ischemic brain damage using photochemically induced MCA thrombosis model in guinea pigs. FK419, ozagrel, or argatroban was administered 5 min after the termination of photoirradiation. FK419 dose-dependently improved MCA patency by decreasing the total occlusion time, time to continuous reperfusion, and the number of cyclic flow reductions, at doses that inhibited ADP-induced platelet aggregation ex vivo. In contrast, ozagrel only improved total occlusion time, and argatroban showed no improvement in MCA patency. FK419 also reduced ischemic brain damage in a dose-dependent fashion, whereas ozagrel and argatroban did not. Finally, FK419 ameliorated neurological deficits, whereas ozagrel and argatroban did not. These results indicate that FK419, a GPIIb/IIIa antagonist, ameliorates ischemic brain damage by improving MCA patency after occlusion and that FK419 is a promising candidate for the treatment of acute ischemic stroke. |
| | |
Authors:
|
Akira Moriguchi; Toshiaki Aoki; Kayoko Mihara; Nobuteru Tojo; Nobuya Matsuoka; Seitaro Mutoh |
Related Documents
:
|
7508898 - Modulation of the activity and assessment of the receptor selectivity in a series of ne... 10516408 - A quick simple method of determining platelet aggregability following glycoprotein iib/... 15744548 - Gpiib/iiia inhibitor-induced dethrombosis. 11375248 - Platelet gpiib/iiia binding characteristics of small molecule rgd mimetic: distinct bin... 942768 - Platelet-bound and free serotonin levels in jugular and forearm venous blood during mig... 16941138 - Role of the locus coeruleus carbon monoxide pathway in endotoxin fever in rats. |
Publication Detail:
|
Type: Journal Article Date: 2003-11-21 |
Journal Detail:
|
Title: The Journal of pharmacology and experimental therapeutics Volume: 308 ISSN: 0022-3565 ISO Abbreviation: J. Pharmacol. Exp. Ther. Publication Date: 2004 Mar |
Date Detail:
|
Created Date: 2004-02-26 Completed Date: 2004-04-06 Revised Date: 2004-12-08 |
Medline Journal Info:
|
Nlm Unique ID: 0376362 Medline TA: J Pharmacol Exp Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 1094-101 Citation Subset: IM |
Affiliation:
|
Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan. akira_moriguchi@po.fujisawa.co.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antithrombins / therapeutic use* Blood Coagulation / drug effects Blood Platelets / drug effects, physiology Brain Ischemia / complications, drug therapy Disease Models, Animal Guinea Pigs Infarction, Middle Cerebral Artery / drug therapy* Male Methacrylates / therapeutic use Pipecolic Acids / therapeutic use Platelet Aggregation Inhibitors / therapeutic use* Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors* Reperfusion Injury / prevention & control Thromboxane B2 / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Antithrombins; 0/Methacrylates; 0/Pipecolic Acids; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 54397-85-2/Thromboxane B2; 74863-84-6/argatroban; 82571-53-7/ozagrel |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mammalian voltage-gated calcium channels are potently blocked by the pyrethroid insecticide allethri...
Next Document: Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle i...